On 23 December 2024 the National Institute for Health and Care Excellence (NICE) published the Technology Appraisal in relation to tirzepatide (Mounjaro™) which is a new drug for managing obesity.
This medication is now available in Bedfordshire, Luton and Milton Keynes for certain groups of people with higher levels of obesity and at least four co-morbidities (other conditions). The medication is currently only available through our specialist weight management clinics, as we work through a process and undertake clinical steps before for this is available for patients on prescription.
In the short term this medication will not be available from GP practices, NICE have indicated in the guidance that it could take up to 12 years to make it fully available to the eligible population.
Please see the FAQs about tirzepatide (Mounjaro™), which provide more information on what this means for Bedfordshire, Luton and Milton Keynes residents.